Year: 2025
Type: article
Abstract: Cancer immunotherapies, including immune checkpoint blockade and engineered T cell therapies, have revolutionized cancer treatment but face challenges from cancer-specific heterogeneity, tumor-immune interaction complexity, age-associated immune alteration and interspecies limitations. Advances in organoid technologies, using the patient-derived, self-organizing three-dimensional tissues, provide physiologically relevant platforms to model tumor-immune interactions and evaluate therapies in a cancer- and patient-specific manner. This platform has significantly enhanced the predictive power of preclinical research and facilitated more effective immunotherapy development.
Source: npj Biomedical Innovations.
Authors: Xiaowo Kang, Sriya K. Cheemalamarri, Qian Yin
Institutions: The University of Texas at Austin, Texas Materials Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W4417283867